A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 27 Nov 2023
At a glance
- Drugs JP 2266 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Jeil Pharmaceutical
Most Recent Events
- 27 Nov 2023 New trial record